The Effect of Dorzolamide-timolol Eye drop on Intraocular Pressure Change in Intravitreal Ranibizumab Injected Patients

Basit Öğe Kaydı
dc.authoridcoskun, mehmet/0000-0001-7315-2994
dc.contributor.authorCoskun, Mehmet
dc.date.accessioned2024-09-29T16:08:27Z
dc.date.available2024-09-29T16:08:27Z
dc.date.issued2023
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPURPOSE: The objective of the study was to examine the effect of dorzolamide-timolol (DT) eye drop used before intravitreal ranibizumab (IVR) injection on intraocular pressure (IOP) change.METHODS: 50 eyes of 50 patients who received DT eye drops 1 h before IVR injection due to diabetic retinopathy and macular edema were considered Group 1, and 50 eyes of 50 patients who did not receive DT eye drops were considered Group 2. Those patients who had previously undergone intravitreal injection had intraocular surgery, and used any eye drops were not included in the study. Before the injection, IOP values were measured with a Tonopen contact handheld tonometer before the blepharostat was placed (BIOP), after the blepharostat was placed (AIOP), and at the 1st min after the injection (IIOP).RESULTS: There were 25 males and 25 females in Group 1 and 25 males and 25 females in Group 2; the mean age was 65.66 +/- 9.94 years in Group 1 and 65.54 +/- 7.43 years in Group 2 (P = 0.98). In Group 1, BIOP was 18.91 +/- 18.91, AIOP was 21.62 +/- 6.16 mmHg, and IIOP was 49.21 +/- 10.95 mmHg. In Group 2, BIOP was 20.18 +/- 4.19 mmHg, AIOP was 24.60 +/- 4.90 mmHg, and IIOP was 49.96 +/- 9.72 mmHg. IIOP-BIOP difference was 30.30 +/- 9.85 mmHg in Group 1 and 29.78 +/- 9.33 mmHg in Group 2 and the difference was not statistically significant (P = 0.78). In Group 1, the IIOP-AIOP difference was 27.58 +/- 10.60 mmHg and in Group 2, 25.36 +/- 10.46 mmHg. The difference between IIOP and AIOP was not statistically significant (P = 0.27).CONCLUSION: The use of topical DT eye drops before IVR injection does not affect the intraocular pressure change.en_US
dc.identifier.doi10.4103/meajo.meajo_177_23
dc.identifier.endpage88en_US
dc.identifier.issn0974-9233
dc.identifier.issn0975-1599
dc.identifier.issue2en_US
dc.identifier.pmid39006931en_US
dc.identifier.scopus2-s2.0-85196404652en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage85en_US
dc.identifier.urihttps://doi.org/10.4103/meajo.meajo_177_23
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7549
dc.identifier.volume30en_US
dc.identifier.wosWOS:001253562300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofMiddle East African Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-glaucomatous eye dropen_US
dc.subjectintraocular pressureen_US
dc.subjectintravitreal injectionen_US
dc.titleThe Effect of Dorzolamide-timolol Eye drop on Intraocular Pressure Change in Intravitreal Ranibizumab Injected Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu